Faculty Profiles - IMAI Norihiro

Papers - IMAI Norihiro

Division display 101 - 112 of about 112 ／ All the affair displays >>

A case of intractable hepatic encephalopathy successfully treated by oral administration of vancomycin hydrochloride, with subsequent improvement of hepatic function reserve enabling transcatheter arterial chemoembolization against hepatocellular carcinoma

Kuzuya T.

Japanese Journal of Cancer and Chemotherapy Vol. 38 ( 6 ) page： 995 - 997 2011.6

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analogues treatment in chronic hepatitis B

HOSAKA Tetsuya, SUZUKI Fumitaka, KOBAYASHI Masahiro, SEKO Yuya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yusuke, SEZAKI Hitomi, AKUTA Norio, SUZUKI Yoshiyuki, SAITOH Satoshi, ARASE Yasuji, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Kanzo Vol. 52 ( 4 ) page： 255 - 257 2011.6

Publishing type：Research paper (scientific journal) Publisher：The Japan Society of Hepatology

Clearance of HBsAg is considered the ultimate goal in the treatment for chronic hepatitis B. We analyzed clinical factors associated with HBsAg clearance during long-term nucleot(s)ide analogue treatment. By univariate analysis, HBV genotype, family history of HBV infection, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were significant predictive factors. By multivariate analysis, HBV genotype, previous IFN therapy, HBeAg clearance at 6 months, and undetectable HBV DNA at 6 months were independent and significant predictive factors of HBsAg clearance. We conclude that patients with genotype A have high probability of HBsAg clearance, and it seems that not only the antiviral potential of nucleot(s)ide analogue but host immune response is needed to achieve HBsAg clearance.

DOI： 10.2957/kanzo.52.255

Scopus

researchmap

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Arase Y

Hepatology Research Vol. 41 ( 6 ) page： 524 - 529 2011.6

Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model.

Ikeda K, Kobayashi M, Kawamura Y, Imai N, Seko Y, Hirakawa M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Liver international : official journal of the International Association for the Study of the Liver Vol. 31 ( 5 ) page： 692 - 9 2011.5

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

SUZUKI Yoshiyuki, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SEKO Hiroya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yuusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, ARASE Yasuji, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Kanzo Vol. 52 ( 2 ) page： 147 - 149 2011.4

Publishing type：Research paper (scientific journal) Publisher：The Japan Society of Hepatology

To further improve therapeutic effect on chronic hepatitis C, we have administered NS3 inhibitor and NS5A inhibitor together, and examined effects of early antiviral agent therapy. The subjects were five cases where interferon is ineffective (null responders). The NS5A and NS3 inhibitors are oral drugs and were daily administered for 24 weeks. Figure 1 shows time-dependent change of the number of viruses after the therapy started, and rapid decrease of viruses is recognized. Within 12 hours, HCV-RNA decreased by more than 2 log IU/ml in every patient. Two patients became negative for the virus by the 15th day after the therapy started. Furthermore, 80% of cases by the 28th day and all the cases by the 56th day became negative. The new therapy has manifested excellent early antiviral effect.

DOI： 10.2957/kanzo.52.147

Scopus

researchmap

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Arase Y, Suzuki Y, Suzuki F, Matsumoto N, Akuta N, Imai N, Seko Y, Sezaki H, Kawamura Y, Kobayashi M, Hosaka T, Saito S, Ikeda K, Kobayashi M, Kumada H

Internal medicine (Tokyo, Japan) Vol. 50 ( 19 ) page： 2083 - 8 2011

Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Oncology Vol. 80 ( 3-4 ) page： 188 - 94 2011

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation : A retrospective study of hepatitis C virus-related liver cancer

IKEDA Kenji, KOBAYASHI Masahiro, SEKO Yuya, IMAI Norihiro, HIRAKAWA Miharu, KAWAMURA Yusuke, SEZAKI Hitomi, HOSAKA Tetsuya, AKUTA Norio, SAITOH Satoshi, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology Vol. 40 ( 12 ) page： 1168-1175 2010.12

Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosis

IMAI Norihiro, IKEDA Kenji, SEKO Yuya, HIRAKAWA Miharu, KAWAMURA Yusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

Kanzo Vol. 51 ( 12 ) page： 758 - 760 2010.12

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Society of Hepatology

Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting severe liver cirrhosis, there is no prospective data regarding clinical toxicity of miriplatin in HCC patients with severe cirrhosis. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 34 HCC patients with severe liver cirrhosis (Child-Pugh grade B). An anti-tumor effect of complete response was achieved in 8 of 34 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safety for HCC patients with Child-Pugh B liver cirrhosis.

DOI： 10.2957/kanzo.51.758

Scopus

researchmap

A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy

Imai N.

Japanese Journal of Cancer and Chemotherapy Vol. 37 ( 3 ) page： 527 - 529 2010.3

High Incidence of Colonic Perforation During Colonoscopy in Hemodialysis Patients With End-Stage Renal Disease

Imai Norihiro, Takeda Kinichi, Kuzuya Teiji, Utsunomiya Setsuo, Takahashi Hiroshi, Kasuga Hirotake, Asai Masami, Yamada Michiko, Tanikawa Yutaka, Goto Hidemi

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 8 ( 1 ) page： 55 - 59 2010.1

A case of hepatitis b-related multiple hepatocellular carcinomas, most of which lead to necrosis possibly due to the implantation of an arterial infusion catheter

Kuzuya T.

Japanese Journal of Cancer and Chemotherapy Vol. 36 ( 12 ) page： 2377 - 2379 2009.11

　 PREV - NEXT 　

<IMAI Norihiro>

Papers - IMAI Norihiro